A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: Results from two randomized, parallel-group, placebo-controlled trials

Annals of Medicine

Volumn 43, Issue 8, 2011, Pages 594-605

  Cryer, Byron L ^a   Sostek, Mark B ^b   Fort, John G ^c   Svensson, Ola ^d   Hwang, Clara ^b   Hochberg, Marc C ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c POZEN Inc   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Celecoxib; Drug therapy combination; Dyspepsia; Esomeprazole; Heartburn; MSODA; Naproxen; Proton pump inhibitors; Tolerability; Upper gastrointestinal tract

Indexed keywords

CELECOXIB; ESOMEPRAZOLE PLUS NAPROXEN; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MODIFIED SEVERITY OF DYSPEPSIA ASSESSMENT; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SINUSITIS; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSPEPSIA; FEMALE; GASTROINTESTINAL TRACT; HEARTBURN; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OMEPRAZOLE; OSTEOARTHRITIS, KNEE; PYRAZOLES; SULFONAMIDES; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 80555136041     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.625971     Document Type: Article

References (37)

1. Altman R, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43:1905-15.
2. Desai SP, Solomon DH, Abramson SP, Buckley L, Crofford L, Cush JJ, et al. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum. 2008;59:1058-73.
3. Lanza FL, Chan FK, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728-38.
4. National Institute for Health and Clinical Excellence. The care and management of osteoarthritis in adults. NICE clinical guideline 59. Available at: http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf (accessed 17 December 2010).
5. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther K-P, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669-81. (Pubitemid 40559291)
6. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137-62. (Pubitemid 351222155)
7. Straus WL, Ofman JJ, MacLean C, Morton S, Berger ML, Roth EA, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia Definitions. Am J Gastroenterol. 2002;97:1951-8.
8. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9.
9. Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005;129: 1753-5.
10. Scheiman JM. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. Am J Manag Care. 2001;7: S10-14. (Pubitemid 32170770)
11. Spiegel BMR, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006;119:448.e27-36.
12. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010;32:1240-8.
13. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-42. (Pubitemid 46648649)
14. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118: 1894-909.
15. Chan FKL, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the first international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol. 2008;103:2908-18.
16. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007;369:1580-1. (Pubitemid 46710106)
17. Lai K-C, Chu K-M, Hui W-M, Wong BCY, Hu WHC, Wong W-M, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271-8. (Pubitemid 41566529)
18. Hawkey CJ, Jones RH, Yeomans ND, Scheiman JM, Talley NJ, Goldstein JL, et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2007;25:813-21. (Pubitemid 46434908)
19. Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Langstrom G, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol. 2005;100:1028-36. (Pubitemid 40769038)
20. Latimer N, Lord J, Grant RL, O'M ahony R, Dickson J, Conaghan PG, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009;339:b2538.
21. Sturkenboom MCJM, Burke TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford). 2003;42 (Suppl 3):iii23-31.
22. Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol. 2006;4:1337-45.
23. Sturkenboom MCJM, Burke TA, Tangelder MJD, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18:1137-47. (Pubitemid 38021600)
24. Abraham NS, El-Serag HB, Johnson ML, Hartman C, Richardson P, Ray WA, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2005;129:1171-8. (Pubitemid 41446857)
25. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103:323-32. (Pubitemid 351248716)
26. van Soest EM, Sturkenboom MCJM, Dieleman JP, Verhamme KMC, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26:265-75. (Pubitemid 46985490)
27. Food and Drug Administration (FDA). VIMOVO™ prescribing information. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/ 2010/022511lbl.pdf (accessed 17 December 2010).
28. Electronic Medicines Compendium (eMC). Summary of Product Characteristics. VIMOVO 500 mg/20 mg modifiedrelease tablets. Available at: http://www.medicines.org.uk/EMC/medicine/23883/SPC/VIMOVO-500-mg-20-mg-modified- release-tablets (accessed 17 December 2010).
29. Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin. 2011;27:1243-53.
30. Welle J, Fort J, Crawley J, Cryer B, Dickerhoof R, Turner MP, et al. Modified Severity of Dyspepsia Assessment pain scale: a new tool for measuring upper abdominal pain in osteoarthritis patients taking NSAIDs. Patient Relat Outcome Meas. 2011;2:135-43.
31. Rabeneck L, Cook KF, Wristers K, Souchek J, Menke T, Wray NP. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol. 2001;54:755-65. (Pubitemid 32722178)
32. Rabeneck L. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors. Rheumatology (Oxford). 2003;42 (Suppl 3) :iii32-9. (Pubitemid 37407012)
33. Rabeneck L, Goldstein JL, Vu A, Mayne TJ, Rublee DA. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. Am J Gastroenterol. 2005;100:1043-50. (Pubitemid 40769040)
34. Rabeneck L, Wristers K, Goldstein JL, Eisen G, Dedhiya SD, Burke TA. Reliability, validity, and responsiveness of Severity of Dyspepsia Assessment (SODA) in a rand omized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol. 2002;97:32-9. (Pubitemid 34059761)
35. Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. entericcoated naproxen alone. Aliment Pharmacol Ther. 2010;32: 401-13.
36. Goldstein JL, Hwang C, Datto C. Correlation of two patientreported outcomes to assess dyspepsia: patients listening to their gut feeling. Poster presented at the American College of Gastroenterology Annual Scientific Meeting, San Antonio, TX, USA, 15-20 October 2010.
37. Sostek M, Fort J, Estborn L, Vikman K. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAIDassociated gastric ulcers. Curr Med Res Opin. 2011;27: 847-54.